DCTH

#2702
Delcath Systems, Inc. - Common Stock
10.7 8 USD
+9744.75%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
10.78
10.78
Faixa anual
0.11
12.27
Mudança diária
+9744.75%
Mudança mensal
+5.27%
Mudança em 6 meses
+13.24%
Mudança anual
+4.26%
Fechamento anterior
0.1 1
Open
10.7 8
Mínimo
10.7 8
High
10.7 8
Volume
62
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 372.14 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Dispositivos médicos
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
144.29
Índice preço/fluxo de caixa
4.73

Delcath Systems, Inc. - Common Stock

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

Notícias